Alzheimer’s disease is a neuroinflammatory, neurodegenerative condition, characterized by progressive deterioration of cognitive function and loss of short-term memory and executive function. More...
Formal diagnosis of Alzheimer’s disease has historically been dependent on the presence of extraneuronal amyloid beta (Ab) plaques, which can only be observed at autopsy or with the aid of sophisticated radioimaging techniques.
Diagnostic methods have recently been approved that quantify Ab in peripheral blood and correlate well with imaging results, however Ab plaques can also be found in people without apparent AD symptoms, which has cast doubt about the role of Ab as the central mediator of disease pathology. The results of the pharmaceutical industry’s focus on Ab centric drug development have been disappointing.
BioVie has a different approach, which focuses on the root cause of the disease, inflammation. We are developing NE3107, which has a unique mechanism of action and pharmaceutical characteristics that could provide an opportunity to change the trajectory of the burden of Alzheimer’s care and improve the lives of millions Alzheimer’s patients and their caregivers.